Molecular Diagnostics for Transplant Market Research Report Information by Product (Reagents & Kits, Instruments, and Services & Software), by Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, and Others), by End User (Hospitals and Transplant Centers, Research Laboratories & Academic Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest of The World) - Forecast Till 2030

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES

4.2.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTIC TECHNIQUES

4.2.3 INCREASING NUMBER OF TRANSPLANT PROCEDURES

4.3 RESTRAINTS

4.3.1 STRINGENT RULES AND REGULATIONS FOR PRODUCT APPROVAL

4.3.2 DEARTH OF SKILLED LABOR

4.4 OPPORTUNITIES

4.4.1 GROWING PUBLIC AWARENESS ABOUT ORGAN DONATION AND TRANSPLANTATION

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES SERVICES AND REVIEW

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON GLBOAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

5.3.1 IMPACT ON DEMAND

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON KEY PLAYERS

5.4 QUALITATIVE OVERVIEW FOR INFECTIOUS DISEASE VIRUSES

5.4.1 CYTOMEGALOVIRUS (CMV)

5.4.2 EPSTEIN-BARR VIRUS (EBV)

5.4.3 BK POLYOMAVIRUS (BKV)

5.4.4 HUMAN HERPESVIRUS 6 (HHV-6)

5.4.5 ADENOVIRUS

5.4.6 HERPES SIMPLEX VIRUS (HSV)

5.4.7 PARVOVIRUS

5.4.8 JOHN CUNNINGHAM VIRUS (JCV)

5.4.9 HEPATITIS E VIRUS (HEV)

5.4.10 OTHERS

6 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT

6.1 OVERVIEW

6.2 REAGENTS & KITS

6.3 INSTRUMENTS

6.4 SERVICES & SOFTWARE

7 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY

7.1 OVERVIEW

7.2 POLYMERASE CHAIN REACTION (PCR)

7.3 SEQUENCING

7.4 MICROARRAY

7.5 OTHERS

8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS AND TRANSPLANT CENTERS

8.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES

8.4 OTHERS

9 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION

9.1 INTRODUCTION

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL

10.6.2 PARTNERSHIP/AGREEMENT

10.6.3 MERGER /ACQUISTION

10.7 FINANCIAL MATRIX

10.7.1 SALES (USD MILLION), 2021

10.7.2 R&D EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILE

11.1 BIOMÉRIEUX SA

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCT OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 THERMO FISHER SCIENTIFIC INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCT/SERVICE OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 CEPHEID

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCT/SERVICE OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 KEY STRATEGIES

11.4 ALTONA DIAGNOSTICS GMBH

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 KEY STRATEGIES

11.5 ELITECHGROUP

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 F. HOFFMANN-LA ROCHE LTD

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 HOLOGIC, INC.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS/SERVICES OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 QIAGEN N.V.

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 BECTON, DICKINSON AND COMPANY 

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 SWOT ANALYSIS

11.9.6 KEY STRATEGIES

11.10 ABBOTT

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030(USD MILLION)

TABLE 3 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR REAGENTS & KITS, BY REGION, 2018–2030(USD MILLION)

TABLE 4 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR INSTRUMENTS, BY REGION, 2018–2030(USD MILLION)

TABLE 5 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SERVICES & SOFTWARE, BY REGION, 2018–2030(USD MILLION)

TABLE 6 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030(USD MILLION)

TABLE 7 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018–2030(USD MILLION)

TABLE 8 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SEQUENCING, BY REGION, 2018–2030(USD MILLION)

TABLE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR MICROARRAY, BY REGION, 2018–2030(USD MILLION)

TABLE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018–2030(USD MILLION)

TABLE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030(USD MILLION)

TABLE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2018–2030(USD MILLION)

TABLE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018–2030(USD MILLION)

TABLE 14 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018–2030(USD MILLION)

TABLE 15 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 17 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 18 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 19 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 20 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 21 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 22 US: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 23 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 24 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 25 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 26 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 27 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 28 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 29 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 30 GERMANY MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 31 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 32 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 33 UK MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 34 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 35 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 36 FRANCE MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 37 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 38 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 39 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 40 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 41 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 42 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 43 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 44 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 45 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 46 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 47 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 48 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 49 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 50 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 52 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 53 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 54 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 55 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 56 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 57 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 58 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 59 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 60 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 61 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 62 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 63 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 64 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 65 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 66 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 67 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 68 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 69 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 70 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 71 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 72 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 73 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 74 MIDDLE EAST MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 75 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 76 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 77 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 78 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 79 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 80 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)

TABLE 81 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 82 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 83 MAJOR PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

TABLE 84 MOST ACTIVE PLAYER IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

TABLE 85 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 86 PARTNERSHIP/AGREEMENT

TABLE 87 MERGER/ACQUISTION

TABLE 88 BIOMÉRIEUX SA: PRODUCT OFFERED

TABLE 89 BIOMÉRIEUX SA: KEY DEVELOPMENTS

TABLE 90 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERED

TABLE 91 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS

TABLE 92 CEPHEID: PRODUCT/SERVICE OFFERED

TABLE 93 CEPHEID: KEY DEVELOPMENTS

TABLE 94 ALTONA DIAGNOSTICS GMBH: PRODUCTS OFFERED

TABLE 95 ALTONA DIAGNOSTICS GMBH: KEY DEVELOPMENTS

TABLE 96 ELITECHGROUP: PRODUCTS OFFERED

TABLE 97 ELITECHGROUP: KEY DEVELOPMENTS

TABLE 98 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED

TABLE 99 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS

TABLE 100 HOLOGIC, INC: PRODUCTS OFFERED

TABLE 101 HOLOGIC INC.: KEY DEVELOPMENTS

TABLE 102 QIAGEN N.V.: PRODUCTS OFFERED

TABLE 103 QIAGEN N.V.: KEY DEVELOPMENTS

TABLE 104 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED

TABLE 105 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS

TABLE 106 ABBOTT: PRODUCTS OFFERED

TABLE 107 ABBOTT: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET STRUCTURE

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 3 MARKET DYNAMICS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

FIGURE 4 DRIVER IMPACT ANALYSIS

FIGURE 5 RESTRAINT IMPACT ANALYSIS

FIGURE 6 VALUE CHAIN ANALYSIS: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

FIGURE 8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY PRODUCT 2021

FIGURE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION)

FIGURE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION 2021 & 2030 (USD MILLION)

FIGURE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY REGION, 2021

FIGURE 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021

FIGURE 15 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021

FIGURE 16 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021

FIGURE 17 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021

FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET

FIGURE 20 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET: COMPETITIVE LANDSCAPE

FIGURE 21 SALES 2021

FIGURE 22 R&D EXPENDITURE, 2021

FIGURE 23 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 BIOMÉRIEUX SA: SWOT ANALYSIS

FIGURE 25 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS

FIGURE 27 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS

FIGURE 29 HOLOGIC INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 QIAGEN N.V.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 QIAGEN N.V.: SWOT ANALYSIS

FIGURE 32 BECTON, DICKINSON AND COMPANY : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS

FIGURE 34 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT